Science Corp Raises $230M for Vision Brain Implant

Science Corp Closes $230M to Bring Vision-Restoring Brain Implants to Patients

Science Corp, a neurotechnology startup founded by former Neuralink executive Max Hodak, has closed a massive $230 million funding round as it races to bring its brain-implant technology to patients suffering from blindness. The raise marks one of the largest investments in the brain-computer interface (BCI) space outside of Elon Musk's Neuralink, signaling growing investor confidence in the commercial viability of neural implants.

The company's flagship product is a neural implant designed to interface directly with the visual cortex, bypassing damaged eyes or optic nerves to deliver visual information straight to the brain. For the millions of people worldwide living with conditions like retinitis pigmentosa, macular degeneration, and other forms of irreversible blindness, Science Corp's technology represents a potentially transformative breakthrough.

From Neuralink to Science Corp

Max Hodak co-founded Neuralink alongside Elon Musk in 2016 and served as the company's president until his departure in 2021. He launched Science Corp shortly after, drawing on his deep expertise in neural engineering and brain-computer interfaces to tackle a more focused clinical problem: restoring sight.

"We believe vision restoration is the most impactful near-term application of brain-computer interface technology. The visual cortex is well-mapped, the patient need is enormous, and the regulatory pathway is clearer than many people realize." — Max Hodak, CEO of Science Corp

Hodak's decision to narrow the company's focus to vision — rather than pursuing the broader ambitions that characterize Neuralink — has been a deliberate strategic choice. By targeting a specific medical condition with well-understood neuroscience, Science Corp aims to move through clinical trials and regulatory approval more efficiently.

How the Technology Works

Science Corp's implant system consists of several key components:

• A thin-film cortical implant placed on the surface of the visual cortex, featuring thousands of microelectrodes capable of stimulating precise neural patterns.
• An external camera system worn by the patient, which captures real-time visual information from the surrounding environment.
• A processing unit that translates camera input into electrical stimulation patterns the brain can interpret as visual perception.
• Proprietary software algorithms that adapt over time to each patient's unique neural responses, improving image clarity and resolution.

Unlike retinal implants that require a functioning retina, Science Corp's cortical approach can potentially help patients regardless of where in the visual pathway their condition originates. This significantly expands the addressable patient population.

The Growing Neural Implant Landscape

Science Corp enters an increasingly competitive market. Neuralink has grabbed headlines with its first human implant trials focused on paralysis and motor control. Synchron has advanced its own minimally invasive BCI through clinical studies. Meanwhile, companies like Precision Neuroscience and Blackrock Neurotech are pushing the boundaries of electrode density and biocompatibility.

However, Science Corp's exclusive focus on vision restoration gives it a differentiated position. The company argues that vision is among the most tractable BCI applications because decades of neuroscience research have produced detailed maps of how the visual cortex processes information. This foundational knowledge reduces the technical risk compared to more exploratory applications like memory enhancement or cognitive augmentation.

Road to the Clinic

With the new funding, Science Corp plans to accelerate its path toward first-in-human clinical trials, which the company has targeted for late 2026 or early 2027. The capital will also be used to scale manufacturing of its implant hardware, expand its engineering and neuroscience teams, and deepen partnerships with academic medical centers.

Regulatory filings with the FDA are expected in the coming months, and the company has indicated it will pursue a Breakthrough Device designation to expedite the review process. If granted, this could shave years off the typical timeline for bringing a medical device to market.

What This Means for the Future of BCI

The $230M raise underscores a broader trend: brain-computer interface technology is transitioning from laboratory curiosity to clinical reality. Investors are increasingly willing to back companies that can demonstrate clear medical applications, robust safety profiles, and realistic regulatory strategies.

For professionals tracking the intersection of technology and healthcare — whether you are a neuroscience researcher, a medical device engineer, or a product manager exploring BCI platforms — these developments are reshaping career landscapes. Tools like InterviewAlly can help candidates prepare for technical interviews in these rapidly evolving fields.

Science Corp's $230 million milestone is more than a funding event. It is a signal that the era of practical, life-changing brain-computer interfaces may be closer than many anticipated.